Abstract | BACKGROUND: METHODS: A total of 37 patients with newly diagnosed type 2 diabetes were studied. The patients were assigned randomly to treatment for 12 weeks with either acarbose (n=13, 100 mg x 3/day, group A), glimepiride (n=13, 2 mg/day, group G) or diet only (n=11, group D). Lipid and lipoprotein profiles before and after each treatment were evaluated. RESULTS: A significant reduction in the net electronegative charge of low-density lipoprotein (emLDL) was observed in group A (-1.8, P<0.01), whereas no significant change in emLDL was observed in groups G and D. In group A, small VLDL and very small LDL levels were also decreased significantly (P<0.05). The change in emLDL levels correlated significantly with changes in very small LDL (r=0.751, P<0.01) and oxidized LDL levels (r=0.623, P<0.05). CONCLUSION: These results suggest that measurement of serum emLDL may be a sensitive and clinically useful marker for determining qualitative lipoprotein abnormalities in diabetes, and that acarbose treatment lowers CVD risk by decreasing production of emLDL.
|
Authors | Goji Hasegawa, Shizuo Kajiyama, Toru Tanaka, Saeko Imai, Hana Kozai, Aya Fujinami, Mitsuhiro Ohta, Hiroshi Obayashi, Hyohun Park, Koji Nakano, Muhei Tanaka, Emi Shiraishi, Michiaki Fukui, Toshikazu Yoshikawa, Naoto Nakamura |
Journal | Clinica chimica acta; international journal of clinical chemistry
(Clin Chim Acta)
Vol. 390
Issue 1-2
Pg. 110-4
(Apr 2008)
ISSN: 0009-8981 [Print] Netherlands |
PMID | 18230353
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Enzyme Inhibitors
- Glycoside Hydrolase Inhibitors
- Hypoglycemic Agents
- Lipoproteins, LDL
- Acarbose
|
Topics |
- Acarbose
(pharmacology, therapeutic use)
- Diabetes Mellitus, Type 2
(drug therapy, metabolism)
- Enzyme Inhibitors
(pharmacology, therapeutic use)
- Glycoside Hydrolase Inhibitors
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Lipoproteins, LDL
(metabolism)
|